What Is CBG and CBN? Differences, Effects, and Benefits

CBG (cannabigerol) and CBN (cannabinol) are two non-intoxicating cannabinoids found in the cannabis plant, but they come from completely different origins and act on the body in distinct ways. CBG is often called the “parent” or “stem cell” cannabinoid because its acidic form serves as the chemical precursor from which THC, CBD, and other major cannabinoids are synthesized. CBN, by contrast, is a breakdown product that forms when THC degrades over time, especially with heat and light exposure. Despite both being marketed in similar-looking supplement bottles, their pharmacology, the research behind them, and the practical reasons someone might use one over the other are quite different.

Where They Come From

CBG starts its life as cannabigerolic acid (CBGA), the first cannabinoid the cannabis plant produces. Enzymes in the plant then convert CBGA into the precursors of THC, CBD, and CBC. Because most CBGA gets converted during the plant’s growth, mature cannabis flowers typically contain very little CBG, usually under one percent. Breeders have developed high-CBG hemp strains that harvest early or lack the enzymes that convert CBGA, which is how supplement companies get enough raw material to make CBG products.

CBN follows a completely different path. It does not come from an enzymatic process inside the living plant. Instead, it forms when THC breaks down through exposure to heat, oxygen, or ultraviolet light. Researchers studying this degradation process found that THC converts to CBN at measurable rates when cannabis resin is stored at temperatures as low as 50°C, with faster conversion at higher temperatures.¹ Old cannabis that has been sitting around for months or years will naturally accumulate more CBN as its THC content drops. This origin story matters because it tells you something fundamental about each compound: CBG is the starting material, while CBN is the end product of aging and degradation.

How CBG Works in the Body

CBG interacts with the body through several pathways, and researchers are still mapping out the full picture. Unlike THC, CBG does not appear to strongly activate the CB1 receptors in the brain that produce a high. Instead, it touches a wider set of targets at more modest levels. One area of interest is its interaction with serotonin and noradrenaline signaling. In rat brain tissue, CBG reduced the effectiveness of drugs that activate alpha-2 adrenoceptors and 5-HT1A serotonin receptors, and the same study found that CBG produced anxiety-reducing effects in live rats through the serotonin 5-HT1A receptor system.² That serotonin connection is part of why CBG gets attention for mood and anxiety.

CBG also activates certain ion channels involved in pain sensing. It stimulates and then desensitizes the TRPV1 channel, which is the same receptor that capsaicin (the compound in hot peppers) activates.³ It was also identified as an antagonist of TRPM8, a cold-sensing channel linked to certain types of pain. Beyond these channels, computational and laboratory work identified CBG as a dual agonist of PPARα and PPARγ, nuclear receptors involved in fat metabolism, inflammation, and insulin sensitivity.⁴ This PPAR activity is one reason researchers think CBG has anti-inflammatory and metabolic potential.

How CBN Works in the Body

CBN’s pharmacology overlaps with THC’s more than CBG’s does, which makes sense given that CBN literally comes from THC. CBN acts as a partial agonist at both CB1 and CB2 cannabinoid receptors, with a stronger effect at CB2. Its metabolite CBN-11-OH interacts with CB1 with greater potency, which may help explain some of CBN’s reported sedative and psychoactive properties, though these effects are considerably weaker than THC’s.⁵ CBN also binds to both CB1 and CB2 receptors, but the binding profile differs from THC’s in important ways: the phenolic hydroxyl group in CBN’s structure influences its affinity for both receptors differently than the equivalent group does in THC.⁶

Like CBG, CBN also interacts with TRP channels involved in pain perception. CBN was found to be a potent activator and desensitizer of TRPA1, a channel associated with inflammatory and neuropathic pain, but it did not significantly activate TRPV2, which many other cannabinoids do.³ The broader picture is that cannabinoids hit different combinations of these sensory channels, and CBN’s particular pattern is distinct from CBG’s.⁷

What the Research Says About CBG’s Benefits

The majority of CBG research is preclinical, meaning it comes from cell cultures and animal models rather than human trials. That said, the results across several areas are consistent enough that researchers keep pushing forward.

Gut inflammation is one of the strongest areas. In a mouse model of colitis, CBG reduced markers of tissue damage and inflammation, including the enzyme myeloperoxidase, and normalized levels of key inflammatory signaling molecules. The researchers concluded that CBG could be considered for clinical testing in inflammatory bowel disease patients.⁸ A more recent study using a high-CBG hemp extract in a similar colitis model found dramatic reductions in disease severity, including longer colon length (a sign of less inflammation-driven tissue shrinkage), less tissue damage, and positive shifts in the gut microbiome.⁹

Neuroprotection is another active area. In mice modeled for Huntington’s disease, CBG improved motor deficits, preserved neurons in the brain region most affected by the disease, and reduced inflammatory markers from overactive immune cells in the brain. While the effects were strongest in a toxin-induced model, even the genetically engineered Huntington’s mice showed modest but significant improvements.¹⁰ A systematic review confirmed that CBG and its derivatives showed neuroprotective efficacy in animal models, with some of those effects mediated through PPAR-γ receptors.¹¹

CBG has also shown antibacterial properties. Laboratory experiments found that CBG was active against methicillin-resistant Staphylococcus aureus (MRSA), inhibiting biofilm formation and even eradicating preformed biofilms. The compound worked by targeting the bacterial cell membrane, and it showed effectiveness in a live mouse infection model as well.¹² Separate research confirmed that both CBG and CBD showed antimicrobial activity against planktonic bacteria and biofilms, with the ability to remove mature biofilms at concentrations below their minimum inhibitory concentrations.¹³

Additional preclinical findings include reduced intraocular pressure (relevant to glaucoma), antioxidant effects, and appetite stimulation.¹⁴ A study using a CBG analog (CBG-DMH) demonstrated that it lowered eye pressure in rats through a mechanism independent of the CB1 and CB2 receptors, which is interesting because CB1 activation causes the psychoactive effects people associate with cannabis.¹⁵

CBG in Humans for Anxiety and Stress

The evidence gap between animal models and human experience is where things get frustrating for consumers, and this is worth being honest about. For a long time, there were no published clinical trials of CBG in people. That changed recently with a small double-blind, placebo-controlled crossover trial involving 34 healthy adults. Compared to placebo, CBG significantly reduced self-reported anxiety overall and reduced stress at the first measurement point. It did not produce noticeable subjective drug effects or impair motor or cognitive performance.¹⁶

This is encouraging, but a 34-person trial is a starting point, not a conclusion. It tells us CBG probably does something measurable for anxiety in the short term and does not appear to be intoxicating, which lines up with what users report anecdotally. What it cannot tell us is optimal dosing, how long the effects last with regular use, or how it compares to established treatments. If you are considering CBG for anxiety, it is reasonable to try, but temper expectations with the understanding that the human evidence is still thin.

What the Research Says About CBN’s Benefits

CBN’s most marketed claim is that it helps with sleep, and this is the one area where there is now a properly designed human trial to evaluate. A double-blind, placebo-controlled study with 293 participants tested 20 mg of CBN (alone and combined with CBD) against placebo over two weeks. The 20 mg CBN group showed significantly reduced nighttime awakenings and overall sleep disturbance compared to placebo. However, CBN did not significantly improve how quickly people fell asleep or total time spent awake after initially falling asleep. Adding CBD to CBN did not improve the results. Crucially, there was no increase in daytime fatigue, which is a common problem with traditional sleep aids.¹⁷

The sleep finding is real but narrower than how it gets advertised. CBN appears to help people stay asleep rather than fall asleep faster. If your problem is waking up multiple times during the night, CBN might help. If your problem is lying awake for an hour before sleep onset, this trial suggests CBN is not the right tool.

Beyond sleep, CBN has shown appetite-stimulating effects in rats, increasing feeding behavior through CB1 receptor activation. This stands in contrast to CBD, which reduced food intake in the same study, and CBG, which had no effect on feeding at all.¹⁸ This appetite effect may be relevant for people dealing with appetite loss from illness or treatment, though again, this has only been studied in animals so far.

CBN and Drug Testing

This is a practical concern that catches people off guard. Because CBN is structurally similar to THC, it can trigger a false positive on standard urine drug tests. Two commonly used immunoassays both showed cross-reactivity with CBN. One assay needed about five times more CBN than THC metabolite to hit the positive threshold, while the other needed about twenty times more. When CBN was present alongside actual THC metabolite, the signals were additive, meaning even small amounts of CBN could push a borderline test result over the cutoff.¹⁹

A confirmatory test (gas chromatography–mass spectrometry) can distinguish CBN from THC metabolites, so a false positive can be resolved. But the initial screening result could still cause problems in workplace or legal settings before that confirmatory test happens. If you are subject to drug testing, CBN products carry more risk than CBG products in this regard. CBG does not share the same structural similarity to THC and has not been reported to cause the same cross-reactivity issue.

Safety and Drug Interactions

Neither CBG nor CBN has been through the kind of large-scale safety testing that prescription drugs undergo. The human trials that exist did not report serious adverse effects, but these were short-term studies with limited numbers of participants. At the cellular level, one concern that applies to both compounds (and to cannabinoids broadly) is their potential to interfere with how your body processes other medications. A study evaluating twelve different cannabinoids found that nearly all of them inhibited the liver enzyme CYP2C9, with potency values suggesting this inhibition could matter at real-world doses. This enzyme metabolizes drugs like warfarin, certain anti-inflammatory medications, and some diabetes drugs. The researchers noted that in vivo drug interaction studies may be justified for anyone taking CYP2C9 substrates with a narrow therapeutic index, meaning drugs where small changes in blood levels can cause problems.²⁰

If you take blood thinners, anti-seizure medications, or other drugs that require careful dose management, talk to your doctor before adding CBG or CBN supplements. The interaction risk is not hypothetical; the enzyme inhibition data are clear. What remains less certain is how much of an oral CBG or CBN supplement actually reaches the liver at concentrations high enough to matter, since absorption and metabolism vary by person and product formulation.

Side-by-Side Comparison

Because these two cannabinoids get lumped together in marketing, it helps to see where they actually differ:

Origin: CBG comes from the plant’s own biosynthesis as a precursor molecule. CBN forms from THC degradation after harvest.
Psychoactivity: CBG shows no evidence of producing a high. CBN has weak CB1 activity and its metabolites are mildly psychoactive, though far less than THC.
Primary research interest: CBG is studied most for inflammation, neuroprotection, antimicrobial effects, and anxiety. CBN is studied most for sleep maintenance and appetite stimulation.
Human trial data: CBG has one small anxiety trial showing benefit. CBN has a larger sleep trial showing reduced nighttime awakenings.
Drug test risk: CBN cross-reacts with THC immunoassays. CBG does not carry the same risk.
Appetite effects: CBN increases appetite in animal studies. CBG does not appear to affect feeding behavior.

What Products Actually Contain

The supplement market for minor cannabinoids is poorly regulated, and this creates real practical problems. CBG and CBN products are sold as oils, tinctures, capsules, and gummies, typically derived from hemp. Because these compounds are present in low concentrations in the raw plant, extraction and purification costs are higher than for CBD, and you will usually pay a premium. The CBG products on the market tend to come from specially bred high-CBG hemp strains harvested early, while CBN products are sometimes made by deliberately aging or heating THC-containing cannabis to accelerate the conversion process.

Third-party lab testing (a certificate of analysis, or COA) matters here more than for CBD products. You want to confirm not only that the CBG or CBN content matches the label, but also that THC levels are below the legal limit (0.3% delta-9-THC in the United States for hemp-derived products). For CBN products, this is especially relevant because the starting material was THC, and incomplete conversion could leave residual THC in the final product. A reputable company will post batch-specific COAs that include cannabinoid profiles, pesticide screens, and heavy metal tests.

Doses Used in Research Versus What Products Offer

There is a disconnect between the doses studied in clinical settings and what you find on supplement shelves. The human CBN sleep trial used 20 mg nightly, and many commercial CBN products fall in the 5 to 25 mg range, so there is reasonable overlap. The human CBG anxiety trial used a higher dose, and many commercial CBG products offer 10 to 50 mg per serving. Animal studies used doses in the range of 5 to 20 mg per kilogram of body weight for neuroprotective effects, which would translate to very large human doses that nobody is taking in supplement form.¹¹

Bioavailability is the other variable. How much of an oral cannabinoid actually makes it into your bloodstream depends on whether it is in an oil base, whether you take it with food (especially fatty food), and individual differences in gut absorption and liver metabolism. Two people taking the same 20 mg CBN gummy could end up with meaningfully different amounts in their system. This is not unique to cannabinoids; it is a feature of most fat-soluble supplements. But it does mean that finding your effective dose may require some experimentation.

Why CBN Is Not Simply “the Sleepy Cannabinoid”

The reputation of CBN as a sedative cannabinoid predates the clinical evidence and may be partly a misattribution. Older cannabis with higher CBN content also tends to have higher levels of sedating terpenes like myrcene and linalool, which develop or concentrate as other compounds degrade. People who smoked old cannabis and felt sleepy may have been responding to the terpene profile, the remaining THC, or the combination of everything together rather than CBN specifically. The clinical trial described earlier does support that CBN helps with sleep maintenance, but its overall effect on subjective sleep quality just missed statistical significance. Calling CBN a “sleep cannabinoid” is an oversimplification that the data only partially support. It helps with nighttime waking, not with falling asleep or total sleep quality in a clean, dramatic way.